3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
Conditions
Multiple Endocrine Neoplasia Type 1
1
Coronary Disease
1
Interventions
Everolimus
8
lanreotide
7
Octreotide
7
lutetium Lu 177 dotatate
6
pasireotide
5
Thyrotropin Alfa
5
Mitotane
4
Etoposide
4
Doxorubicin
4
177Lu-octreotide, DOTA(0)-Tyr(3)-
4
amino-acid, glucose, and electrolyte solution
3
Mifepristone
3
Filgrastim
3
Corlux
3
Cisplatin
3
Chemotherapy, Adjuvant
3
Capecitabine
3
Cabergoline
3
vandetanib
2
telotristat ethyl
2
surufatinib
2
ribociclib
2
fluorodopa F 18
2
cabozantinib
2
Temozolomide
2
Receptor-Like Protein Tyrosine Phosphatases, Class 2
2
Lutetium-177
2
Lutetium
2
Leucovorin
2
Iodine-131
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
evolocumab
×
Endocrine
×
Clear all
NCT03872401
2025-11-10
VESALIUS-CV
Amgen
Phase 3
Completed
12,301 enrolled